FATE has 36-month beta value of 2.22. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for FATE is 107.09M, and currently, short sellers hold a 8.88% ratio of that float. The average trading volume of FATE on June 26, 2025 was 2.07M shares.
FATE) stock’s latest price update
Fate Therapeutics Inc (NASDAQ: FATE)’s stock price has plunge by -2.59relation to previous closing price of 1.16. Nevertheless, the company has seen a -6.61% plunge in its stock price over the last five trading sessions. zacks.com reported 2025-06-12 that Fate Therapeutics (FATE) reported earnings 30 days ago. What’s next for the stock?
FATE’s Market Performance
Fate Therapeutics Inc (FATE) has experienced a -6.61% fall in stock performance for the past week, with a -7.38% drop in the past month, and a 32.30% rise in the past quarter. The volatility ratio for the week is 8.62%, and the volatility levels for the past 30 days are at 10.86% for FATE. The simple moving average for the last 20 days is -14.41% for FATE stock, with a simple moving average of -37.99% for the last 200 days.
Analysts’ Opinion of FATE
Piper Sandler, on the other hand, stated in their research note that they expect to see FATE reach a price target of $6, previously predicting the price at $4. The rating they have provided for FATE stocks is “Overweight” according to the report published on June 17th, 2024.
Wells Fargo gave a rating of “Equal Weight” to FATE, setting the target price at $6 in the report published on March 27th of the previous year.
FATE Trading at -7.85% from the 50-Day Moving Average
After a stumble in the market that brought FATE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.91% of loss for the given period.
Insider Trading
Bressi Jerome Charles, the See Remarks of Fate Therapeutics Inc, sale 5,980 shares at $1.55 during a trade that took place back on Jan 10 ’25, which means that Bressi Jerome Charles is holding 270,203 shares at $9,269 based on the most recent closing price.
Stock Fundamentals for FATE
Current profitability levels for the company are sitting at:
- -15.03 for the present operating margin
- -1.59 for the gross margin
The net margin for Fate Therapeutics Inc stands at -13.19. The total capital return value is set at -0.54. Equity return is now at value -49.23, with -36.32 for asset returns.
Based on Fate Therapeutics Inc (FATE), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -1.48.
Currently, EBITDA for the company is -176.58 million with net debt to EBITDA at -0.23. When we switch over and look at the enterprise to sales, we see a ratio of 12.59. The receivables turnover for the company is 5.54for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.81.
Conclusion
To put it simply, Fate Therapeutics Inc (FATE) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
